- The FDA has issued a recall for some Dexcom glucose monitors due to a speaker defect.
- Analysts forecast a potential 19.24% upside for Dexcom within the next year.
- Dexcom's GF Value suggests a possible 100.95% growth from its current price.
The FDA has recalled certain models of Dexcom (DXCM, Financial) glucose monitors, including the G6, G7, ONE, and ONE+, due to a speaker defect that may prevent users from receiving alerts for critical glucose levels. This defect has led to 56 reported injuries, highlighting the significant health risks associated with these products.
Analyst Insights and Price Forecasts
Wall Street analysts have projected one-year price targets for DexCom Inc (DXCM, Financial), with 26 analysts suggesting an average target price of $100.28. The high estimate stands at $115.00, and the low is $85.00. This average target indicates a potential upside of 19.24% from the current price of $84.10. For a more in-depth analysis, visit the DexCom Inc (DXCM) Forecast page.
Moreover, DexCom Inc's (DXCM, Financial) average brokerage recommendation from 28 firms is 1.7, labeling it as an "Outperform." This rating scale ranges from 1 to 5, where 1 signifies a Strong Buy, and 5 indicates a Sell.
GF Value Estimate for Dexcom
According to GuruFocus estimates, the GF Value for DexCom Inc (DXCM, Financial) over the next year is projected at $169.00. This suggests a potential upside of 100.95% from the current price of $84.1. The GF Value represents the fair value at which the stock should trade, based on historical trading multiples, past business growth, and future business performance forecasts. More comprehensive data can be found on the DexCom Inc (DXCM) Summary page.
